TB-500
Coverage of TB-500 in the Nexus archive.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA's upcoming peptide safety review panel includes health professionals with financial ties to the peptide industry, a shift from previous academic-focused panels. The meeting, influenced by Health Secretary Robert F. Kennedy Jr.'s 'Make America Healthy Again' movement, will assess peptides like BPC-157 and TB-500, which the FDA has warned are unproven and risky.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The FDA's upcoming panel to review controversial peptide drugs includes health professionals with financial ties to the industry, including clinics and pharmacies promoting unproven peptides. The meeting follows concerns about the safety and regulatory status of substances like BPC-157 and TB-500, which are marketed for wellness purposes but lack scientific validation. Health Secretary Robert F. Kennedy Jr. has publicly supported these peptides.
- FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures
The FDA plans to review easing restrictions on seven peptides, including BPC-157 and TB-500, amid pressure from Health Secretary Robert F. Kennedy Jr. and his allies. Critics warn that unregulated peptide use poses significant safety risks, as these substances lack clinical testing and FDA approval.